Figure 1.
CONSORT diagram of the ENHANCE-2 trial. 7+3 chemotherapy, 7 days of continuous IV cytarabine (100 or 200 mg/m2 daily) and 3 days of IV daunorubicin (60 mg/m2 daily) or idarubicin (12 mg/m2 daily) on days 1 through 3.
CONSORT diagram of the ENHANCE-2 trial. 7+3 chemotherapy, 7 days of continuous IV cytarabine (100 or 200 mg/m2 daily) and 3 days of IV daunorubicin (60 mg/m2 daily) or idarubicin (12 mg/m2 daily) on days 1 through 3.
